Showing 15 posts of 48 posts found.


FDA approves BioMarin’s Roctavian for adults with severe haemophilia A

June 30, 2023
Medical Communications BioMarin, FDA, Haematology, Roctavian, haemophilia

Global biotechnology company BioMarin Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Roctavian (valoctocogene roxaparvocec-rvox) …

uniQure announces sale of royalty interest in Hemgenix for up to $400m

May 16, 2023
Sales and Marketing Haematology, Hemgenix, haemophilia, royalties, uniQure

uniQure has announced that it has entered a definitive agreement to sell a portion of the royalty rights due to …


US approval for haemophilia drug derived from genetically engineered rabbit’s milk

April 2, 2020
Sales and Marketing FDA, US, haemophilia, pharma

The FDA has announced the approval of Sevenfact, a haemophilia therapy the active ingredient from which is expressed in genetically …


Novo Nordisk halts three haemophilia studies after participants suffer thrombotic events

March 17, 2020
Manufacturing and Production, Research and Development Novo Nordisk, haemophilia, pharma

Novo Nordisk has moved to temporarily shut down two of its Phase 3 and one of its Phase 2 clinical …


NHS Scotland gives green light to funding haemophilia A drug Hemlibra

December 18, 2019
Research and Development NHS, haemophilia, haemophilia B, haemophilia a, nhs scotland

NHS Scotland has commissioned Hemlibra (emicizumab), by Chungai Pharma UK Ltd and Roche Products Ltd, to treat people with congenital …


Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy

December 17, 2019
Manufacturing and Production haemophilia, haemophilia B, haemophilia a

The Republic of Ireland’s Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) and Sobi United Kingdom and Republic of Ireland, …


NHS England to fund Hemlibra for patients with severe haemophilia

August 21, 2019
Research and Development Chugai, Hemlibra, Roche, haemophilia, pharma

NHS England is to fund Roche and Chugai Pharma UK’s haemophilia drug Hemlibra, for people with sever congenital haemophilia A …


Roche unveils wave of strong Hemlibra data in haemophilia A with or without factor VIII inhibitors

July 9, 2019
Manufacturing and Production, Research and Development Roche, haemophilia, pharma

Roche revealed a swathe of new data on Hemlibra (emicizumab) at the International Society on Thrombosis and Haemostasis (ISTH) 2019 …


Pfizer and Sangamo’s haemophilia A gene therapy shows promise at Phase 1/2

July 8, 2019
Research and Development, Sales and Marketing Pfizer, Sangamo, haemophilia, pharma

Pfizer and Sangamo Therapeutics have shared new Phase 1/2 data for their investigational SB-525 gene therapy in the treatment of …


European approval for Novo’s Esperoct in haemophilia A

June 21, 2019
Medical Communications, Sales and Marketing Esperoct, Novo Nordisk, haemophilia, pharma

The European Commission has awarded approval to Novo Nordisk’s extended half-life factor VIII therapy Esperoct (turoctocog alfa pegol, N8-GP) for …

Sangamo and Pfizer’s gene therapy increases FVIII activity in severe haemophilia A in early study

April 3, 2019
Research and Development, Sales and Marketing Pfizer, Sangamo, haemophilia, pharma

Sangamo Therapeutics and Pfizer have unveiled new Phase 1/2 data for their jointly developed investigational gene therapy SB-525, demonstrating that …


Roche scores two EU approvals in haemophilia and rare autoimmune disease

March 15, 2019
Medical Communications EC, EU, Europe, Roche, haemophilia, rare diseases

The European Commission (EC) has approved Roche’s haemophilia treatment Hemlibra (emicizumab). The approval comes as the EC approved Roche’s MabThera …


Roche and Chugai’s Hemlibra scoops up EU approval in the prevention of severe haemophilia A without factor VIII inhibitors

March 14, 2019
Sales and Marketing Chugai, Hemlibra, Roche, haemophilia, pharma

Roche has announced along with its partner Chugai that Hemlibra (emicizumab) has secured approval from the European Commission as a …

Pfizer’s biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018

December 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASH 2018, Pfizer, haemophilia

Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new …


Hemlibra shows “clinically meaningful” bleed control in paediatric haemophilia A patients

December 4, 2018
Manufacturing and Production, Research and Development ASH 2018, Hemlibra, Roche, haemophilia, pharma

In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for …

Latest content